Another ongoing phase III RCT is evaluating the efficacy, safety, and tolerability of T-Dxd compared with chemotherapy in patients with HER2-low, hormone receptor (HR)-positive metastatic BC whose disease has progressed on endocrine therapy (DESTINY-BREAST 06) [13]. The gene discussed is ERBB2; the disease is breast cancer.